Home › Research › Biomarkers
Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice
O'Bryant SE, Petersen M, Hall J, Johnson LA, HABS-HD Study Team.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022-03-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers. Methods Plasma biomarkers of amyloid beta (Aβ) 40, Aβ 42 , total tau, and neurofilament light chain (NfL) were measured across cognitively normal Mexican Americans (n = 445) and non-Hispanic Whites (n = 520). Results Dyslipidemia was associated with elevated Aβ 40 (P = .01) and Aβ 42 (P = .001) while hypertension was associated with elevated Aβ 40 (P = .003), Aβ 42 (P < .001), and total tau (P = .002) levels. Diabetes was associated with higher Aβ 40 (P < .001), Aβ 42 (P < .001), total tau (P < .001), and NfL (P < .001) levels. Chronic kidney disease (CKD) was associated with elevations in Aβ 40 (P < .001), Aβ 42 (P < .001), total tau (P < .001), and NfL (P < .001) levels. Mexican Americans had significantly lower Aβ 40 (P < .001) and higher total tau (P = .005) levels. Discussion Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. These findings are important for those using these biomarkers in clinical practice and clinical trials.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
O'Bryant, S. E., Petersen, M., Hall, J., Johnson, L. A., & HABS-HD Study Team. (2023). Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.12647
Vancouver
O'Bryant SE, Petersen M, Hall J, Johnson LA, HABS-HD Study Team. Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. doi:10.1002/alz.12647. PMID: 35235702.
BibTeX
@article{obryant2023-35235702,
author = {O'Bryant, S. E. and Petersen, M. and Hall, J. and Johnson, L. A. and {HABS-HD Study Team}},
title = {{Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2023},
doi = {10.1002/alz.12647},
pmid = {35235702},
url = {https://doi.org/10.1002/alz.12647}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Introduction Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers.
- Results Dyslipidemia was associated with elevated Aβ 40 (P = .01) and Aβ 42 (P = .001) while hypertension was associated with elevated Aβ 40 (P = .003), Aβ 42 (P < .001), and total tau (P = .002) levels.
- Diabetes was associated with higher Aβ 40 (P < .001), Aβ 42 (P < .001), total tau (P < .001), and NfL (P < .001) levels.
- Chronic kidney disease (CKD) was associated with elevations in Aβ 40 (P < .001), Aβ 42 (P < .001), total tau (P < .001), and NfL (P < .001) levels.
- Mexican Americans had significantly lower Aβ 40 (P < .001) and higher total tau (P = .005) levels.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants445
- Evidence strengthLow
How this study scored 52/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 445 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35235702) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “important”
3 studies in the library carry the topic tag “important”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.